Puma – PHARMA
Puma – PHARMA
Puma Men – PHARMA
Puma Biotechnology Surging
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Puma – PHARMA
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Puma Biotechnology
Puma Biotechnology
Buy Hering Pharma Muira Puma Mother Tincture Q 30ml | ShopHealthy.in
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma – PHARMA
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Pharma (@PumaPharma) / Twitter
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
PHARMA JONPI .: 08/24/14
PharmaBg
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
